Epitalon: benefits, evidence and legal status

Epitalon (also spelled epithalon; Ala-Glu-Asp-Gly) is a synthetic four-amino-acid peptide modeled on epithalamin, a calf pineal gland extract. It is not approved by the FDA for any use, and its strongest evidence comes from cell and animal studies.

The research is intriguing. In human cells grown in the lab, epitalon switched on telomerase, the enzyme that rebuilds the protective caps at the ends of chromosomes [Lab] (Khavinson 2003), and in old monkeys it raised evening melatonin [Animal] (Goncharova 2001). Human data are thin: FDA’s July 2026 review found no human pharmacokinetic or safety studies, and ClinicalTrials.gov lists no registered epitalon trial.

Item	Status
US FDA	Not approved; not a component of any FDA-approved drug (FDA briefing, 2026)
Compounding (503A/503B)	Withdrawn from Category 2 by its nominators (FDA, page of April 22, 2026). FDA’s Pharmacy Compounding Advisory Committee reviewed it on July 24, 2026 (FDA meeting page); FDA has posted no vote tally or minutes. The vote is advisory; FDA staff had recommended against, and no FDA rule has followed yet
WADA 2026	Not named; S0 covers substances with no current approval by any government health authority (WADA 2026 List)
UK / EU / Australia / Canada	No approved epitalon product; none authorized by the EMA (FDA briefing)
Strongest evidence	Lab and animal studies, mostly from one Russian research group; one small placebo-controlled human study on a melatonin marker
Human trials	0 registered on ClinicalTrials.gov
Last checked	2026-10-08

Identity	Value
Sequence	Ala-Glu-Asp-Gly (4 amino acids)
Molecular formula	C14H22N4O9 (free base)
Molecular weight	390.35 g/mol (free base); acetate salt 450.40 g/mol
CAS	307297-39-8 (free base); 307297-40-1 (acetate)
PubChem CID	219042
Half-life	Not measured; FDA found no pharmacokinetic data in humans
Routes studied	Sublingual, parabulbar injection (humans); subcutaneous, intramuscular, intravenous (animals)
Class	Synthetic pineal peptide (“bioregulator”); studied in ageing research

What is epitalon?

Epitalon was developed in Saint Petersburg, Russia, by researchers working under Vladimir Khavinson. It was built from the amino-acid makeup of epithalamin, a polypeptide extract of cattle pineal glands, and FDA describes it as a “synthetic analog” of that extract (FDA briefing). A 2025 review notes that the tetrapeptide was made before it was actually detected in the pineal extract, and that its structure and chemistry are still little studied (Araj 2025). Most of the published pharmacology comes from Khavinson’s group. It is sold online as an “anti-aging” peptide, and FDA found clinics promoting it as “the fountain of youth” on the strength of telomerase claims. The PubChem record lists the synonyms epithalon, epithalone and Ala-Glu-Asp-Gly.

How does epitalon work?

No receptor for epitalon has been identified. The proposed mechanisms come from lab and animal work, much of it from the developers’ group.

• Telomerase activation: in telomerase-negative human fetal fibroblasts, epitalon induced the enzyme’s catalytic subunit, its activity and longer telomeres [Lab] (Khavinson 2003).
• Telomere maintenance in other cells: an independent group saw dose-dependent telomere lengthening in normal human cells through telomerase, and through ALT in breast cancer cells [Lab] (Al-Dulaimi 2025).
• Pineal and melatonin signalling: epitalon raised evening melatonin in old rhesus monkeys [Animal] (Goncharova 2001), yet it did not trigger melatonin release from isolated rat pineal glands [Lab] (Djeridane 2003), so the route is indirect or unknown.
• Chromatin effects: in cultured lymphocytes from people aged 76–80, epitalon activated ribosomal genes and loosened tightly packed chromatin [Lab] (Khavinson 2003b).
• Antioxidant activity: in mouse egg cells, epitalon lowered reactive oxygen species and reduced cell death after 24 hours [Lab] (Yue 2022).

What the research shows

The table grades each common claim by the strongest evidence behind it, following the site’s editorial policy and methodology. Animal rows describe mice, rats, monkeys or flies, not people.

Claim	Evidence level	Best study and result
Activates telomerase	Lab	Khavinson 2003: enzyme induced, telomeres longer in fetal fibroblasts
Lengthens telomeres (independent lab)	Lab	Al-Dulaimi 2025: dose-dependent in normal cells; via ALT in cancer cells
Extends cell lifespan	Lab	Khavinson 2004: 10 extra divisions beyond passage 34
Changes telomeres in human blood cells	Lab, donor cells (n=11)	Khavinson 2019: longer in 5, shorter in 2
Raises melatonin in old primates	Animal	Goncharova 2001: evening melatonin up over 4-fold (FDA summary)
Restores a melatonin marker in people	Human RCT (n=40, per FDA briefing)	Ivko 2020: urinary 6-sulfatoxymelatonin up 1.7-fold
Improves sleep or insomnia	No study	FDA 2026: no study of sleep outcomes found
Extends lifespan in mice	Animal (54 per group)	Anisimov 2003: mean unchanged; maximum +12.3%
Extends lifespan in flies	Animal	Khavinson 2000: +11–16% in fruit flies
Fewer or smaller tumors	Animal	Anisimov 2002: fewer, smaller breast tumors in HER-2/neu mice
Fewer chromosome aberrations	Animal	Rosenfeld 2002: down 17.9–30.1% in three mouse strains
Helps retinitis pigmentosa	Human, uncontrolled (n not given)	Khavinson 2002: “positive clinical effect in 90% of the cases”
Reduces inflammation	Lab	Avolio 2022: lower TNF and IL-6 in human monocyte cells

Telomeres and cell ageing

Telomere work is the most cited part of the epitalon story. In the developers’ experiments, ageing fetal lung fibroblasts stopped dividing at passage 34, while epitalon-treated cells regained early-passage telomere length and reached passage 44 [Lab] (Khavinson 2004). The encouraging news for the field is that a group at Brunel University London, with no declared competing interests, reproduced telomere lengthening in normal human cells in 2025 [Lab] (Al-Dulaimi 2025). The same study found that in two breast cancer cell lines epitalon lengthened telomeres by activating ALT, a telomere-maintenance route used by some tumors. In blood cells from 11 men, telomere length rose in 5 and fell in 2 after exposure [Lab] (Khavinson 2019). No study has measured telomeres in people taking epitalon.

Lifespan and tumors in animals

In female mice injected for life, epitalon did not change average lifespan, food intake or body weight, but the longest-lived 10% lived 13.3% longer and leukemia was 6.0-fold less common [Animal] (Anisimov 2003). In a separate strain, mean survival rose 5.3% [Animal] (Anisimov 2001). In rats given a colon carcinogen, treated groups averaged 2.7 and 2.9 tumors per rat versus 4.1 in controls [Animal] (Anisimov 2002b). An Israeli-Russian team saw no metastases in treated older mice versus 3 of 9 tumor-bearing controls [Animal] (Kossoy 2006). In rats kept under standard lighting, lifespan did not change [Animal] (Vinogradova 2007). FDA reviewers noted that its three mouse cancer studies used one fixed dose, female mice only and short total exposure.

Melatonin, circadian rhythm and sleep

In old female rhesus monkeys, ten days of epitalon raised evening melatonin more than fourfold and lowered evening cortisol by about 30%, restoring the normal day-night cortisol pattern; young monkeys showed no melatonin change [Animal] (FDA briefing). In women aged 40–50 who mostly worked night shifts, a sublingual epitalon spray for 20 days raised the urinary melatonin breakdown product 6-sulfatoxymelatonin 1.7-fold from baseline, with no change on placebo, and shifted clock-gene expression [Human RCT, n=40] (Ivko 2020; design as summarized in the FDA briefing). FDA noted that the paper did not specify blinding and measured no sleep outcomes. FDA found no animal or human study of epitalon’s effect on sleep itself.

Eyes and other areas

In Campbell rats, which inherit retinal degeneration, treating both the mothers (before mating and during pregnancy) and their offspring preserved retinal structure and function about twice as long as in controls [Animal] (Khavinson 2003c). Lab studies also report anti-inflammatory effects [Lab] (Avolio 2022), and old rats showed antioxidant changes [Animal] (Kozina 2007).

Human studies and trials

There are no completed, registered clinical trials of epitalon, and a search of ClinicalTrials.gov for epitalon, epithalon and related names returns no studies. FDA’s 2026 review found three published human studies of the synthetic peptide.

Study	Design and n	Result
Ivko 2020 (FDA cites as 2021)	Randomized, placebo-controlled; 75 women, 40 randomized; sublingual, 20 days (design per FDA briefing) (design per FDA briefing)	6-sulfatoxymelatonin up 1.7-fold; no sleep or safety data reported
Khavinson 2021 (per FDA)	Sublingual, night-shift workers	Changes in circadian gene expression
Khavinson 2002	Uncontrolled; parabulbar injection; n not stated in abstract	Retinitis pigmentosa: “positive clinical effect in 90% of the cases”
Korkushko 2007	Elderly people and old monkeys; n not stated in abstract	Night melatonin rose in people with low pineal function
ClinicalTrials.gov	Registry search	0 registered trials

Longer human studies exist for epithalamin, the pineal extract, not for epitalon. In 266 older people followed for 6–8 years, mortality was reported 1.6–1.8-fold lower in the epithalamin group than in controls (Khavinson and Morozov 2003), and a randomized comparison in 39 versus 40 heart patients reported lower mortality with epithalamin added to standard care (Korkushko 2011). Both came from the same research network, and FDA does not treat epithalamin results as evidence for epitalon.

Doses used in studies

The amounts below describe what researchers gave in published studies. They are not recommendations.

Route and amount	Species	Study
Subcutaneous, 1 µg per mouse (about 30–40 µg/kg), intermittent courses	Mice	Anisimov 2003
Subcutaneous, 0.1 µg per animal, intermittent courses	Mice	Anisimov 2001
Intramuscular, 2 µg/kg daily for 10 days	Rhesus monkeys	Goncharova 2001, per FDA
Intravenous, single 30 µg/kg (labelled tracer)	Pregnant rabbits	Lapina 2005
Sublingual spray, 0.5 mg per day for 20 days	Humans (women 40–50)	Ivko 2021, per FDA
Cell culture, 50 ng/mL for 4 days	Human fetal fibroblasts	Khavinson 2003, per FDA

No established human dose exists outside approved labels.

Side effects and safety

The safety record is mostly a record of what has not been studied. FDA’s review concluded that “there are no clinical data to support the safety” of epitalon in humans and found no human pharmacokinetic data.

• Reported adverse effects: none documented in a structured way. The placebo-controlled study reported no safety data, and one Russian abstract says the pineal preparations had “no side effects” without giving methods [Human] (Korkushko 2007). FDA’s FAERS database had no reports through December 8, 2025, and its foods and supplements complaint system had none through December 5, 2025.
• Toxicology gaps: FDA identified no acute toxicity, repeat-dose toxicity, reproductive toxicity or two-year carcinogenicity study. Two small mouse studies (4 per group) found fewer chromosome aberrations, not more, but used a single fixed dose.
• Theoretical cancer concern: FDA reasons that a substance that activates telomerase and lengthens telomeres could, with continuous long-term exposure, help cells escape senescence; longer telomeres are linked to higher cancer risk. In one of these mouse studies (Anisimov 2003), FDA calculated that the intermittent courses added up to at most about 22 weeks of exposure. The ALT activation seen in breast cancer cells adds to this open question [Lab] (Al-Dulaimi 2025).
• Immunogenicity: FDA is concerned that injected epitalon could provoke immune reactions because of aggregation and peptide-related impurities (FDA Category 2 page).
• Pregnancy: in pregnant rabbits a fluorescent-labelled dose reached fetal organs [Animal] (Lapina 2005), and no reproductive toxicology exists.
• Product quality: epitalon has no USAN name or pharmacopeia monograph; FDA found suppliers’ certificates that named one form while listing the other’s formula, and no endotoxin testing or identification of individual impurities. Several online sellers label it “research use only” (see what that label means).

Because epitalon has no approved label, no official list of contraindications exists.

Legal and regulatory status

Jurisdiction	Status (checked 2026-10-08)
US FDA	Not approved; not in any approved drug (FDA briefing)
US compounding	Withdrawn from Category 2; reviewed by PCAC on July 24, 2026 after FDA staff advised against listing; vote advisory, no FDA tally posted; not added to the list
US orphan status	Retinitis pigmentosa designation 2010, withdrawn 2016
WADA	Not named in the 2026 or 2027 List; within S0 wording (WADA 2027 List)
UK, EU, Canada, Australia	No approved product; none authorized by the EMA (FDA briefing)

Compounding. Epitalon was one of the peptides placed in FDA’s Category 2 of substances that may present significant safety risks; the nominations were later withdrawn and it now sits in the “nominated but withdrawn” table (FDA Category 2 page). FDA reviewed it anyway, for insomnia only. Its staff concluded that the criteria “weigh against” listing it, citing poor characterization, no human safety data and no evidence of effectiveness (FDA briefing). The committee voted on the free base and the acetate on the morning of July 24, 2026 (FDA questions). FDA has posted no minutes or vote tally on the meeting page. The vote is advice: FDA says it will not make a final determination until the committee’s input is considered (FDA briefing), and it adds substances to the list through notice-and-comment rulemaking (FDA 503A page). FDA also no longer places substances nominated on or after January 7, 2025 into its interim categories. The two pathways are explained in 503A vs 503B compounding.

Sport. Epitalon is not named on the 2026 Prohibited List. Section S0 prohibits at all times any pharmacological substance not covered elsewhere on the List “with no current approval by any governmental regulatory health authority for human therapeutic use”. The 2027 List, in force from January 1, 2027, adds “peptides” to the S0 examples. No government approval of epitalon for human therapeutic use could be found, and FDA found none in the countries it checked, so epitalon falls within the S0 wording; see WADA banned peptides 2027.

Related peptides

• MOTS-c: a mitochondria-derived peptide studied in ageing and metabolism, reviewed at the same July 2026 committee meeting.
• GHK-Cu: a copper-binding tripeptide studied in skin ageing and wound repair, also withdrawn from Category 2.